Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $78.39 USD
Change Today +0.11 / 0.14%
Volume 5.2M
MDT On Other Exchanges
Symbol
Exchange
New York
Mexico
Frankfurt
As of 8:04 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

20 On Hatch

Lower Hatch Street

Dublin, 2

Ireland

Phone: 353 1 438 1700

Fax:

y drug-eluting stent systems, which have received the U.S. FDA approval, as well as Resolute Onyx drug-eluting stent systems, which have received CE Mark approval. Heart Surgery: The company offers a complete line of surgical valve replacement and repair products for damaged or diseased heart valves. The company’s replacement products include both tissue and mechanical valves. The company also offers a line of blood-handling products that form a circulatory support system to maintain and monitor blood circulation and coagulation status, oxygen supply, and body temperature during arrested heart surgery. Additionally, the company offers surgical ablation systems and positioning and stabilization technologies. Aortic and Peripheral Vascular Disease Management (APV) The APV division, which includes a portion of the Covidien Peripheral business, is comprised of a comprehensive line of products and therapies to treat aortic disease (such as aneurysms, dissections, and transections), as well as peripheral vascular disease (PVD). The company’s products include endovascular stent graft systems, peripheral drug coated balloon, stent and angioplasty systems, and carotid embolic protection systems for the treatment of vascular disease outside the heart. The following are the principal products offered by its APV division: Endovascular Stent Grafts: The company’s products are designed to treat aortic aneurysms in either the abdomen (AAA) or thoracic (TAA) regions of the aorta. The company’s product line includes a range of endovascular stent grafts and accessories, including the Endurant II abdominal stent graft system and the Valiant Captivia thoracic stent graft system. Peripheral Vascular Intervention (PVI): The company’s primary PVI products include percutaneous angioplasty balloons, including the IN.PACT family of drug-coated balloons, which have the U.S. FDA and CE Mark approval, as well as peripheral stents, such as the Complete SE Vascular Stent and the Assurant Cobalt Iliac Stent; and directional atherectomy products, such as the TurboHawk plaque excision system, and other products to support procedures. Customers The primary medical specialists who use the Cardiac and Vascular products include electrophysiologists, implanting cardiologists, heart failure specialists, cardiovascular and vascular surgeons and interventional cardiologists and radiologists. Competition The company’s primary competitors are St. Jude Medical, Inc. (St. Jude); Boston Scientific Corporation (Boston Scientific); Sorin Group (Sorin); Edwards Lifesciences Corporation (Edwards); C.R. Bard Inc. (Bard); and Abbott Laboratories (Abbott). Minimally Invasive Therapies Group Surgical Solutions Surgical Solutions develops, manufactures, and markets products and therapies to treat diseases and conditions that are typically addressed by surgeons. In addition, the company develops, manufactures, and markets products in the fields of minimally invasive gastrointestinal diagnostics, ablation, and interventional lung. The following are the principal products offered by the Surgical Solutions division: Surgical Innovations: This business includes sales of stapling, vessel sealing, fixation (hernia mechanical devices), mesh, hardware and surgical instruments, sutures, and electrosurgery products. Key advanced surgical products include the Tri-Staple technology platform for endoscopic stapling, including the Endo GIA reloads and reinforced reloads with Tri-Staple technology and the Endo GIA ultra universal stapler; the iDrive powered stapling systems; the LigaSure vessel sealing system, a multifunctional laparoscopic instrument for use with the ForceTriad; the Sonicision cordless ultrasonic dissection system; AbsorbaTack absorbable mesh fixation device for hernia repair; Symbotex composite mesh for surgical laparoscopic and open ventral hernia repair; and Parietex ProGrip, a selfgripping, biocompatible solution for inguinal hernias. Early Technologies: The company’s products include ablation products, and interventional lung and gastrointestinal solutions. This includes the iLogic System to evaluate lung lesions; the Cool-ti

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDT:US $78.39 USD +0.11

MDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $70.01 USD -0.15
Amgen Inc $176.59 USD +4.90
Bristol-Myers Squibb Co $65.64 USD +1.18
Celgene Corp $131.25 USD -0.63
Eli Lilly & Co $84.51 USD -0.03
View Industry Companies
 

Industry Analysis

MDT

Industry Average

Valuation MDT Industry Range
Price/Earnings 32.5x
Price/Sales 5.5x
Price/Book 2.1x
Price/Cash Flow 32.5x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDTRONIC PLC, please visit www.medtronic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.